Earnings History Data for VYNE Therapeutics (VYNE) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
VYNE Therapeutics
VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29-02-2024 | PM | VYNE | VYNE Therapeutics | 33.00 | -0.20 | -0.50 | 0.00 | 2.22 | -0.11 (-4.72%) |
0.0 | 0.0 (0.00%) |
1.67 - 8.73 | 78,516 | 70,000 | 0 | |||
|
|
||||||||||||||||||
| 13-11-2023 | PM | VYNE | VYNE Therapeutics | 10.00 | -1.85 | -0.76 | 0.00 | VYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1M [11/13/2023 8:43 AM] |
3.42 | -0.09 (-2.56%) |
3.29 | -0.22 (-6.27%) |
1.99 - 8.73 | 116,762 | 2,120,000 | 873 | ||
| 09-03-2023 | AH | VYNE | VYNE Therapeutics | 10.00 | -2.60 | -3.24 | 0.00 | VYNE Therapeutics GAAP EPS of -$2.60 [3/9/2023 5:02 PM] |
2.55 | -0.45 (-14.93%) |
2.93 | -0.07 (-2.33%) |
1.99 - 14.22 | 16,695 | 10,000 | 886 | ||
| 12-08-2022 | PM | VYNE | VYNE Therapeutics Inc. | 27.53 | -0.14 | -0.17 | -0.39 | VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M [8/12/2022 8:24 AM] |
0.3160 | 0.01 (3.95%) |
0.29 | -0.01 (-4.61%) |
0.26 - 2.44 | 577,137 | 770,000 | 38,371 | ||
| 10-11-2021 | PM | 7:30 AM ET (Nov 10) |
VYNE | VYNE Therapeutics Inc. | 70.57 | -0.41 | -0.33 | -0.60 | VYNE Therapeutics EPS misses by $0.04, misses on revenue [11/10/2021 7:36 AM] |
1.31 | -0.05 (-3.68%) |
1.34 | -0.02 (-1.47%) |
1.08 - 13.20 | 527,538 | 600,000 | 31,476 | |
| 12-08-2021 | PM | 7:00 AM ET (Aug 12) |
VYNE | VYNE Therapeutics Inc. | 140.80 | -0.39 | -0.36 | -4.84 | VYNE Therapeutics EPS in-line, misses on revenue [8/12/2021 7:34 AM] |
1.99 | -0.90 (-31.14%) |
2.02 | 0.03 (1.51%) |
1.97 - 13.20 | 4,842,227 | 420,000 | 1,000 | |
|
||||||||||||||||||
| 06-05-2021 | PM | 7:00 AM ET (May 6) |
VYNE | VYNE Therapeutics Inc. | 237.92 | -0.42 | -0.47 | -3.80 | VYNE Therapeutics EPS beats by $0.03, misses on revenue [5/6/2021 7:06 AM] |
3.56 | -0.96 (-21.24%) |
4.12 | -0.40 (-8.85%) |
3.50 - 13.20 | 4,387,647 | 690,000 | 98,754 | |
| 04-03-2021 | PM | 7:00 AM ET (Mar 4) |
VYNE | VYNE Therapeutics Inc. | 373.66 | -0.55 | -0.54 | -3.56 | VYNE Therapeutics EPS beats by $0.08, misses on revenue [3/4/2021 7:53 AM] |
6.66 | -0.74 (-10.07%) |
7.15 | -0.25 (-3.38%) |
4.00 - 17.96 | 2,062,300 | 1,985,835 | 61,726 | |
| 05-11-2020 | PM | VYNE | VYNE Therapeutics Inc. | 298.49 | -0.60 | -0.17 | -0.70 | VYNE Therapeutics EPS beats by $0.02, beats on revenue [11/5/2020 7:25 AM] |
1.77 | 0.05 (2.91%) |
1.77 | 0.0 (0.00%) |
1.00 - 7.48 | 1,506,128 | 1,330,252 | 700 | ||
|
|
||||||||||||||||||